(Z)-2-Acetamido-3-(4-chloro-phen-yl)acrylic acid.

In the title compound, C(11)H(10)ClNO(3), the mol-ecule consists of a benzene ring and an acetamido-acrylic acid unit on opposite sides of the C=C double bond. In the crystal, inter-molecular O-H⋯O and N-H⋯O hydrogen bonds assemble the mol-ecules into infinite two-dimensional ribbons. These ribbons are linked into a network by inter-molecular C-H⋯π contacts.

(Z)-2-Hydr-oxy-3-(4-methoxy-phen-yl)acrylic acid.

In the structure of the title compound, C(10)H(10)O(4), inversion dimers linked by pairs of O-H⋯O hydrogen bonds link the carboxylic acid groups. Further O-H⋯O links cross-link the dimers into sheets running along the b-axis direction.

To tell or not to tell: attitudes of Chinese oncology nurses towards truth telling of cancer diagnosis.

AIMS AND OBJECTIVES: To investigate the attitude of oncology nurses towards whether and how to disclose diagnoses to patients with early-stage cancer or terminal illness. BACKGROUND: The attitudes of patients and doctors towards the disclosure of cancer diagnosis differed from culture to culture. However, little research has focused on the attitudes of Chinese oncology nurses. DESIGN: Survey. METHODS: A questionnaire investigating nurses' attitudes towards truth telling was delivered to 243 Chinese oncology nurses. RESULTS: One hundred and ninety-nine (819%) nurses completed the questionnaire. 814% of the nurses reported that patients with early-stage cancer should be informed of the diagnosis, while only 442% believed that patients with terminal illnesses should know the truth (p < 0001). Nurses who preferred truth telling reported that patients with early or terminal stages of cancer should be informed by the doctor in charge (765% vs. 739%, respectively; p > 005), immediately after the diagnosis (759% vs. 795%, respectively) and in a quiet and undisturbed room (809% vs. 705%, respectively; p > 005). Nurses' attitudes towards truth telling of terminal cancer were influenced by their educational level and work experience. CONCLUSION: Oncology nurses differed in their attitudes towards truth telling of different stages of cancer. Nurses who preferred disclosure reported that cancer patients should be informed by the doctor in charge immediately after the diagnosis and in a quiet and undisturbed room. RELEVANCE TO CLINICAL PRACTICE: Many Chinese doctors, patients and their relatives believed that patients with terminal illness should not know their diagnosis. Thus, oncology nurses need additional training to deal with these situations.

A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer.

PURPOSE: Insufficient sensitivity and specificity prevent the use of most existing biomarkers for early detection of breast cancer. Recently, it was reported that serum microRNAs (miRNAs) may be potential biomarkers in many cancer diseases. In this study, we investigated whether serum levels of 5 miRNAs including miR-21, miR-125b, miR-145, miR-155, and miR-365 could discriminate breast cancer patients and healthy controls. METHODS: Serum levels of miRNAs were measured by using quantitative real-time polymerase chain reaction in 99 breast cancer patients and 21 healthy controls. The abundance change of serum miRNAs were also evaluated following surgical resection in 20 breast cancer patients. Receiver operating characteristic (ROC) curve analysis was performed to assess the sensitivity and specificity of miRNAs as diagnostic biomarkers. RESULTS: Serum levels of miR-21 and miR-155 was significantly higher, while miR-365 was significantly lower in breast cancer as compared with healthy controls. The serum levels of miR-21 and miR-155 significantly decreased following surgical resection. Additionally, the serum level of miR-155 at stages I and II was significantly higher compared to stage III. The serum miR-145 level was remarkably higher in progesterone receptor (PR)-positive patients than PR-negative. The positivity of miR-21, miR-155, and miR-365 was high compared to CA 153 and CEA in breast cancer. ROC curve analyses of a combination of miR-21, miR-155, and miR-365 yielded much higher area under curve and enhanced sensitivity and specificity in comparison to each miRNA alone. CONCLUSION: The combination of serum miR-21/miR-155/miR-365 may potentially serve as a sensitive and specific biomarker that enables differentiation of breast cancer from healthy controls.

One new antitumour cassane-type diterpene from Caesalpinia crista.

1α-acetoxy-5α, 7ß-dihydroxycassa-11,13(15)-diene-16,12-lactone, a new cassane-type diterpene was isolated from Caesalpinia crista. The structure of this compound was elucidated by analysis of NMR spectra, and the relative configuration was established by NOE experiment. The new compound was evaluated for antitumour activity against T47D, DU145 and showed significant inhibitory activities.

Clinicopathologic characteristics and prognosis of young patients with breast cancer.

BACKGROUND: The aim was to describe the clinicopathological features and prognosis of young patients with breast cancer. PATIENTS AND METHODS: We reviewed the records of 1478 consecutive patients aged ≤50 years with first diagnosis of invasive breast cancer referred to surgery from January 1999 to March 2005. A total of 174 patients were aged <35 years (group I) and 1304 were aged 35-50 years (group II). RESULTS: Compared with patients of group II, patients of group I had a higher percentage of tumors classified as estrogen receptors (ER) negative, progesterone receptors (PR) negative, with a Ki-67 labeling index ≥20% of the cells. The 5-year survival of group I was 78.3% as compared with 84.2% for group II (P = 0.006). CONCLUSION: Compared with patients aged between 35 and 50 years, patients aged <35 years have a greater chance of having an endocrine-unresponsive tumor and a significantly poor prognosis.